Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
pDx9Wa5CcK4NqNxr
